Systemic Bottlenecks in Drug Discovery: Fragment Screening as a Catalyst for Efficiency
Original framing: “Accelerating drug discovery with fragment screening” — Phys.org
The original framing omits the historical context of the pharmaceutical industry's prioritization of profit over people, the lack of representation of marginalized communities in clinical trials, and the need for a more holistic approach to health that incorporates traditional knowledge and practices.
Low structural omission detected in mainstream coverage.
This narrative was produced by Phys.org, a reputable science news outlet, for a general audience interested in scientific advancements. The framing serves to highlight the potential of fragment screening as a solution to the challenges in drug discovery, while obscuring the broader structural issues and power dynamics that shape the research process.
The pharmaceutical industry's prioritization of profit over people has led to a systemic crisis in drug development, with many treatments being developed without adequate consideration for their long-term consequences. This has resulted in a range of negative outcomes, including the over-prescription of opioids and the development of antibiotic-resistant bacteria. By examining the historical context of the pharmaceutical industry, researchers can identify key areas for reform and develop more effective solutions.
The acceleration of drug discovery through fragment screening is a symptom of a broader systemic issue in modern medicine: the inefficient allocation of resources and the lack of interdisciplinary collaboration.